| 400 | 4 | 102 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:评价普瑞巴林口服联合利多卡因外用治疗带状疱疹后遗神经痛(PHN)的临床疗效。方法:回顾性分析2019年12月—2022年12月就诊于宜昌市中心人民医院的72例PHN患者的临床资料,随机分为对照组(n=36)和试验组(n=36)。两组患者均口服普瑞巴林,试验组患者后遗神经痛部位联合外用利多卡因凝胶贴膏,记录治疗前后视觉模拟量表(VAS)评分、睡眠质量评分及不良反应发生情况,对比两组患者的临床疗效。结果:两组患者治疗后VAS评分均呈下降趋势,治疗后2周(3.50±1.08 vs 4.50±1.36)、4周(1.75±0.69 vs 2.86±0.90)及6周(0.78±0.68 vs 1.33±0.76)试验组VAS评分均低于对照组(均P<0.05)。治疗后6周两组患者的睡眠质量评分均较前明显降低,且试验组患者的睡眠质量评分低于对照组(9.50±2.85 vs 11.81±2.73,P<0.05)。两组不良反应主要为恶心、头晕及共济失调,但两组不良反应发生率无统计学差异(69.44%vs 80.56%,P>0.05)。结论:普瑞巴林联合利多卡因治疗PHN临床疗效好,可显著降低疼痛程度并改善睡眠质量。
Abstract：Objective: To evaluate the clinical effect of oral pregabalin combined with topical lidocaine in the treatment of post herpetic neuralgia(PHN). Methods: The clinical data of 72 patients with PHN admitted to Yichang Central People's Hospital from December 2019 to December 2022 were retrospectively analyzed. They were randomly divided into the control group(n=36) and the experimental group(n=36). Patients in both groups were given oral pregabalin, and patients in the experimental group were combined with topical lidocaine gel paste at the site of residual neuralgia. Visual analog scale(VAS), sleep quality score and occurrence of adverse reactions were recorded before and after treatment, and the clinical efficacy of the two groups were compared. Results: VAS score in both groups showed a downward trend after treatment. The VAS score of the experimental group were lower than those of the control group at 2 weeks(3.50±1.08 vs 4.50±1.36), 4 weeks(1.75±0.69 vs 2.86±0.90) and 6 weeks(0.78±0.68 vs 1.33±0.76) after treatment(all P<0.05). The sleep quality score of both groups were significantly lower than before, and the sleep quality score of the experimental group was lower than the control group at 6 weeks after treatment(9.50±2.85 vs 11.81±2.73, P<0.05). The main adverse reactions were nausea, dizziness and ataxia, but there was no significant difference between the two groups(69.44% vs 80.56%, P>0.05). Conclusion: Pregabalin combined with lidocaine has good clinical efficacy in the treatment of PHN, which can significantly reduce pain degree and improve sleep quality.
[1] Patil A, Goldust M, Wollina U. Herpes zoster:a review of clinical manifestations and management[J]. Viruses, 2022, 14(2):192.
[2] Mui U N, Haley C T, Vangipuram R, et al. Human oncoviruses:Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention:Hepatitis viruses,human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus[J]. J Am Acad Dermatol, 2019, 81(1):23-41.
[3] Gross G E, Eisert L, Doerr H W, et al. S2k guidelines for the diagnosis and treatment of herpes zoster and postherpetic neuralgia[J]. J Dtsch Dermatol Ges, 2020,18(1):55-78.
[4] Hadley G R, Gayle J A, Ripoll J, et al. Post-herpetic neuralgia:a review[J]. Curr Pain Headache Rep, 2016,20(3):17.
[5]中国医师协会皮肤科医师分会带状疱疹专家共识工作组,国家皮肤与免疫疾病临床医学研究中心.中国带状疱疹诊疗专家共识(2022版)[J].中华皮肤科杂志,2022, 55(12):1033-1040.
[6]中华医学会皮肤性病学分会,中国康复医学会皮肤病康复专业委员会,中国中西医结合学会皮肤性病学分会,等.老年带状疱疹诊疗专家共识[J].中华皮肤科杂志, 2023, 56(2):97-104.
[7] Forbes H J, Thomas S L, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia[J]. Pain, 2016, 157(1):30-54.
[8] Warner B E, Goins W F, Kramer P R, et al. A guide to preclinical models of zoster-associated pain and postherpetic neuralgia[J]. Curr Top Microbiol Immunol, 2021,438:189-221.
[9] Zhou H O, Wang Z G, Jin H F, et al. A systematic review and meta-analysis of independent risk factors for postherpetic neuralgia[J]. Ann Palliat Med, 2021, 10(12):12181-12189.
[10]Bian Z Y, Yu J, Tu M Q, et al. Acupuncture therapies for postherpetic neuralgia:a protocol for a systematic review and Bayesian network meta-analysis[J]. BMJ Open, 2022, 12(3):e056632.
[11]Harpaz R. How little we know Herpes zoster[J]. J Infect Dis, 2020, 222(5):708-711.
[12]Fornasari D, Magni A, Pais P, et al. Changing the paradigm in postherpetic neuralgia treatment:lidocaine 700Mg medicated plaster[J]. Eur Rev Med Pharmacol Sci,2022, 26(10):3664-3676.
[13]Jones J. Postherpetic neuralgia[J]. J Pain Palliat Care Pharmacother, 2015, 29(2):180-181.
[14]《中华医学杂志》社皮肤科慢病能力提升项目专家组,中国医师协会疼痛科医师分会,国家远程医疗与互联网医学中心皮肤科专委会.带状疱疹相关性疼痛全程管理专家共识[J].中华皮肤科杂志, 2021, 54(10):841-846.
[15]魏海明,刘金梅. A型肉毒毒素治疗带状疱疹后神经痛1例[J].医药导报, 2021, 40(5):634-636.
[16]Gónima Valero E, Mendoza W A S, Sarmiento D A, et al. Analgesic treatment approach for postherpetic neuralgia:a narrative review[J]. J Pain Palliat Care Pharmacother, 2023, 37(2):184-193.
[17]Mathieson S, Lin C C, Underwood M, et al. Pregabalin and gabapentin for pain[J]. BMJ, 2020:m1315.
[18]García-González A I, Rosas-Carrasco O. Herpes zoster and post-herpetic neuralgia in the elderly:Particularities in prevention, diagnosis, and treatment[J]. Gac Med Mex, 2017, 153(1):92-101.
[19]刘奎玲,李晓强,孙雪华.利多卡因凝胶贴膏联合加巴喷丁治疗带状疱疹后神经痛[J].中国疼痛医学杂志,2021, 27(5):386-389.
基本信息:
中图分类号:R752.12
引用信息:
[1]丁宗晃,魏青宇,袁春蓉.普瑞巴林联合利多卡因治疗带状疱疹后遗神经痛的临床疗效观察[J].巴楚医学,2023,6(04):75-78.
基金信息:
宜昌市医疗卫生研究项目(No:A21-2-031)
2023-12-30
2023-12-30